Brenda Libby Coleman

Array ( [id] => 17236597 [patent_doc_number] => 11180468 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-23 [patent_title] => Prodrugs of urolithins and uses thereof [patent_app_type] => utility [patent_app_number] => 16/741221 [patent_app_country] => US [patent_app_date] => 2020-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 8874 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 238 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16741221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15895153 [patent_doc_number] => 20200147095 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA [patent_app_type] => utility [patent_app_number] => 16/740410 [patent_app_country] => US [patent_app_date] => 2020-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16740410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15895149 [patent_doc_number] => 20200147093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA [patent_app_type] => utility [patent_app_number] => 16/740329 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16740329 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17029687 [patent_doc_number] => 11091492 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-17 [patent_title] => Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders [patent_app_type] => utility [patent_app_number] => 16/733598 [patent_app_country] => US [patent_app_date] => 2020-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31141 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16733598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428336 [patent_doc_number] => 20220056044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => TRICYCLIC COMPOUNDS AS STING AGONISTS, AND PREPARATION METHODS AND MEDICINAL USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/413287 [patent_app_country] => US [patent_app_date] => 2019-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21617 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17413287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16177290 [patent_doc_number] => 20200224258 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => BIS-BIOTINYLATION TAGS [patent_app_type] => utility [patent_app_number] => 16/708050 [patent_app_country] => US [patent_app_date] => 2019-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21412 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16708050 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16743268 [patent_doc_number] => 10968242 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-06 [patent_title] => Cyclopentane-based modulators of STING (stimulator of interferon genes) [patent_app_type] => utility [patent_app_number] => 16/702738 [patent_app_country] => US [patent_app_date] => 2019-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20459 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16702738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17412628 [patent_doc_number] => 20220047532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => AMPA RECEPTOR ANTAGONISTS SPECIFIC FOR CALCIUM PERMEABLE AMPA RECEPTORS AND METHODS OF TREATMENT THEREWITH [patent_app_type] => utility [patent_app_number] => 17/298599 [patent_app_country] => US [patent_app_date] => 2019-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17298599 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15708643 [patent_doc_number] => 20200101087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => PHARMACEUTICAL COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 16/690282 [patent_app_country] => US [patent_app_date] => 2019-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 95390 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16690282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15678325 [patent_doc_number] => 20200093826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => NEW USE OF TRIAZOLO(4,5 D)PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTION [patent_app_type] => utility [patent_app_number] => 16/688961 [patent_app_country] => US [patent_app_date] => 2019-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12707 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16688961 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17287060 [patent_doc_number] => 11203600 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-21 [patent_title] => Kinase inhibitors and uses thereof [patent_app_type] => utility [patent_app_number] => 16/684340 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53569 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17383800 [patent_doc_number] => 20220031652 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => USE OF AN ORGANOMETALLIC COMPOUND AS A DNA-DEMETHYLATING AGENT [patent_app_type] => utility [patent_app_number] => 17/292689 [patent_app_country] => US [patent_app_date] => 2019-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11726 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15898305 [patent_doc_number] => 20200148671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/681084 [patent_app_country] => US [patent_app_date] => 2019-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57953 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -46 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16681084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15898341 [patent_doc_number] => 20200148689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/681014 [patent_app_country] => US [patent_app_date] => 2019-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74624 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -61 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16681014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16459471 [patent_doc_number] => 10842799 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Serine/threonine kinase inhibitors [patent_app_type] => utility [patent_app_number] => 16/680221 [patent_app_country] => US [patent_app_date] => 2019-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31163 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 305 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16680221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17378071 [patent_doc_number] => 11236068 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => Fused ring compounds [patent_app_type] => utility [patent_app_number] => 16/679104 [patent_app_country] => US [patent_app_date] => 2019-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88482 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16679104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17378071 [patent_doc_number] => 11236068 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => Fused ring compounds [patent_app_type] => utility [patent_app_number] => 16/679104 [patent_app_country] => US [patent_app_date] => 2019-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88482 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16679104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17119647 [patent_doc_number] => 11130769 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-28 [patent_title] => Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein [patent_app_type] => utility [patent_app_number] => 16/679105 [patent_app_country] => US [patent_app_date] => 2019-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 106294 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16679105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16310752 [patent_doc_number] => 20200289490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE [patent_app_type] => utility [patent_app_number] => 16/675982 [patent_app_country] => US [patent_app_date] => 2019-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15724 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16675982 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20239560 [patent_doc_number] => 12419863 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-23 [patent_title] => Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy [patent_app_type] => utility [patent_app_number] => 17/288610 [patent_app_country] => US [patent_app_date] => 2019-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 0 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288610 [rel_patent_id] =>[rel_patent_doc_number] =>)